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T cell receptor (TCR-CD3) triggering involves
both receptor clustering and conformational
changes at the cytoplasmic tails of the CD3 sub-
units. The mechanism by which TCRab ligand
binding confers conformational changes to
CD3 is unknown. By using well-defined ligands,
we showed that induction of the conformational
change requires both multivalent engagement
and the mobility restriction of the TCR-CD3 im-
posed by the plasma membrane. The conforma-
tional change is elicited by cooperative rear-
rangements of two TCR-CD3 complexes and
does not require accompanying changes in the
structure of the TCRab ectodomains. This con-
formational change at CD3 reverts upon ligand
dissociation and is required for T cell activation.
Thus, our permissive geometry model provides
a molecular mechanism that rationalizes how
the information of ligand binding to TCRab is
transmitted to the CD3 subunits and to the intra-
cellular signaling machinery.
INTRODUCTION
Ligand binding and signal transmission functions of the
T cell receptor (TCR-CD3) complex are located on differ-
ent subunits. The TCR-CD3 is composed of the ligand-
binding TCRab (or TCRgd) heterodimer and the signal-
transducing dimers of CD33g, CD33d, and zz. The variable
immunoglobulin (Ig) domains of TCRa and TCRb form the
binding surface for its ligand, the major histocompatibility
complex-peptide (MHCp). The TCRa and TCRb constant
Ig and transmembrane regions couple TCRab to the
CD3 dimers (Call et al., 2002). The CD3 subunits contain
an extracellular Ig domain, a transmembrane region, and
a cytoplasmic tail including several signal-transduction
motifs (Alarcon et al., 2003; Malissen, 2003). The stoichi-
ometry of the TCR-CD3 complex is controversial, and
several distinct stoichiometries might coexist on the cell
surface (Schamel et al., 2005).A central issue in T cell activation is to understand how
the information of MHCp binding to TCRab is transmitted
into the cell via the CD3-signaling units. Two main models
have been put forward, involving TCR-CD3 clustering and
conformational changes (Alarcon et al., 2003; Choudhuri
et al., 2005; Cochran et al., 2001; Germain, 2001; Malis-
sen, 2003; Sigalov, 2005). One model stipulates that
TCR-CD3 clustering by multimeric MHCp brings individual
TCR-CD3 complexes into close proximity, thereby en-
abling transphosphorylation of the receptors by associ-
ated tyrosine kinases. In support of this view, soluble mo-
nomeric MHCp, unlike dimeric or oligomeric MHCp, is
unable to elicit TCR-CD3 activation (Abastado et al.,
1995; Boniface et al., 1998; Cochran et al., 2000; Stone
and Stern, 2006). Similarly, T cells can be stimulated by in-
tact anti-CD3 or anti-TCRab, but not by the corresponding
Fab fragments (Kaye and Janeway, 1984).
Alternatively, conformational changes in the TCR-CD3
complex upon antibody binding have been proposed to
explain T cell-signaling studies because differences in re-
ceptor clustering or in antibody affinities were insufficient
to explain distinct activation potentials of TCR-CD3 anti-
bodies (Janeway, 1995). However, with one exception
(Kjer-Nielsen et al., 2003), crystallographic studies argue
against large conformational changes within the TCRab
Ig ectodomains. Structures from MHCp-bound and
free soluble TCRab revealed ligand-induced structural
changes in the complementarity-determining regions of
the variable Ig domains of TCRab that were not transmit-
ted to TCRab-constant regions (Bankovich and Garcia,
2003; Ding et al., 1999; Reiser et al., 2002; Rudolph
et al., 2006). It is therefore difficult to envisage how li-
gand-induced conformational changes could be transmit-
ted from the TCRab heterodimer to the CD3 tails.
Despite these conceptual problems, the TCR-CD3
complex undergoes a ligand-induced conformational
change that allows a conserved proline-rich sequence
(PRS) in the cytoplasmic tail of CD33 to bind to the first
SH3 (src homology 3) domain of Nck (SH3.1(Nck)), a ubiq-
uitously expressed adaptor protein (Gil et al., 2002). This
structural change can be induced by anti-CD3 and anti-
TCRab as well as by MHCp (Gil et al., 2002, 2005; Risueno
et al., 2005). To date, it is unclear whether Nck recruitment
to TCR-CD3 is a crucial step in T cell activation (Gil et al.,Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc. 43
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TCR-CD3 Conformational Change in T Cell Activation2002; Szymczak et al., 2005) and whether conformational
changes are required for TCR-CD3 triggering. However,
the conformational change is probably a more global
event that also affects the other signaling subunits of the
TCR-CD3 and additional signaling molecules besides
Nck. Indeed, the cytoplasmic tail of the z chain might con-
vert from a lipid-bound helical structure to an unfolded
structure upon TCR-CD3 triggering (Aivazian and Stern,
2000).
By using TCR-CD3 ligands of defined valencies and ge-
ometries, we demonstrated that induction of the confor-
mational change required both multivalent engagement
and the mobility restriction imposed by the membrane.
So far, TCR-CD3 clustering and the conformational
change were discussed as two independent mechanisms
to activate T cells and were not integrated into a unique
model of TCR-CD3 triggering. We showed that TCR-
CD3 clustering was a prerequisite for inducing the confor-
mational change, and it further required the reorientation
of two TCRab heterodimers with respect to each other.
This reorientation resulted in rearrangements within the
TCR-CD3 complex promoting the conformational change.
We also demonstrated that the conformational change of
CD3 was necessary, but not sufficient, for optimal T cell
activation and was reversible upon dissociation of TCR-
CD3-ligand complexes.
RESULTS
Multivalent Engagement of TCRab Is Required
to Induce the Conformational Change
The conformational change leading to exposure of the
PRS of CD33 is induced upon binding of both bivalent
and monovalent antibodies to CD33 (Gil et al., 2002). To
determine whether stimulation with monomeric and multi-
meric MHCp changes the conformation of CD33, we took
advantage of T cells expressing the T1 TCR. This TCR
recognizes the PbCS252-260 peptide (SYIPSAEKI)
containing a photoreactive 4-azidobenzoic acid on K259
(pepABA) (Gregoire et al., 1996) in the context of Kd. After
binding to the T1 TCR, photoactivation of ABA results in
covalent crosslinking of TCRab with MHCp (Doucey
et al., 2003; Gregoire et al., 1996), thereby ‘‘freezing’’ the
interaction between MHCp and TCR-CD3.
Monomeric and tetrameric versions of the KdpepABA
were used to stimulate CD8-negative T1 hybridoma cells.
Both could bind to the T1 TCR, as seen by flow cytometry
(data not shown). After photocrosslinking, the conforma-
tional change in CD33 was detected by the pull-down as-
say with the immobilized SH3.1(Nck) domain. The MHCp
tetramer and CD3 antibody were equally potent in induc-
ing the conformational change (Figure 1A, lanes 3 and
4). In contrast, monomeric MHCp was not able to induce
any conformational change (lane 2), although it bound to
the T1 TCR as shown by the presence of b2-microglobulin
in the anti-CD3 immunoprecipitates (lowest panel). A
comparison of MHCp dimer and tetramer indicated that
both have the same capacity to induce the conformational
change (Figure 1B). In contrast, not all TCR-CD3 anti-44 Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc.bodies had equal capability to induce the conformational
change in CD33 (see Figure S1 in the Supplemental Data
available online). Likewise, complete TCRab antibodies
but not their monovalent Fab fragments induced the con-
formational change (Figure S1). These data showed that
monovalent MHCp binding to TCRab did not induce the
conformational change in TCR-CD3 and that bivalent or
multivalent MHCp engagement was required. Hence, in-
duction of the conformational change in CD33 via TCRab
requires TCR-CD3 clustering.
In the absence of photocrosslinking, the KdpepABA
is not covalently fixed to the T1 TCR (Gregoire et al.,
1996). To test whether the conformational change is
dependent on continuous engagement, T1 hybridomas
were incubated with MHCp tetramers or CD3 antibodies
and subsequently UV irradiated or left unexposed. The
CD33 conformational change was preserved only when
the MHCp-TCR-CD3 interaction was covalently fixed.
When MHCp was not photocrosslinked to TCRab, the
conformational change was not detected (Figure 1C,
lane 2). Nevertheless, in both cases MHCp was bound
to TCR-CD3 (Figure 1D). Upon detergent lysis, MHCp rap-
idly dissociates from TCRab (Arcaro et al., 2001), probably
because of the low MHCp-TCRab affinity. Indeed, the
MHCp tetramer was not detected in an anti-TCR-CD3
immunoprecipitation when UV irradiation was omitted
(Figure 1C, lowest panel), whereas the induction of the
conformational change by CD3 antibodies was indepen-
dent of UV irradiation. The experiment was repeated
with a T1 CTL clone (Doucey et al., 2003) with similar re-
sults (Figure S2). Thus, disruption of MHCp binding most
likely results in reversion of the conformational change.
Next, we tested whether MHCp expressed by antigen-
presenting cells (APCs) can induce the conformational
change. Kd-expressing APCs were loaded with pepABA
and used to stimulate CD8-negative (Figure 1E) and
CD8-positive (Figure 1F) T1 hybridoma cells. Indeed, stim-
ulation with APCs induces the conformational change,
and this induction is independent of CD8 expression.
Thus, induction of the conformational change via TCRab
by MHCp requires multivalent engagement in absence
of any additional interaction.
Close Proximity of Two TCR-CD3 Is Necessary
to Induce the Conformational Change
To exclude that ligand binding was directly altering the
conformation of the TCRab heterodimer, we designed
a system in which the ligand did not directly bind to
TCRab, but only to an appended immunoglobulin single-
chain (sc) construct. The VH and VL regions of an anti-hap-
ten (nitro-iodo-phenol, NIP)-specific antibody were made
as one single-chain molecule and fused to the N terminus
of a mature TCRb chain through a flexible linker (Fig-
ure 2A). The resulting NIP-specific single-chain TCRb pro-
tein (scTCRb) was stably expressed in a TCRb-deficient
Jurkat mutant (31-13), yielding the cell line 31-13.scTCRb.
The scTCRb was expressed within the TCR-CD3 complex
on the cell surface (Figure S3). Because hapten binding to
antibodies does not lead to a change in the structure
Immunity
TCR-CD3 Conformational Change in T Cell ActivationFigure 1. Only Multimerized MHCp Induce the Conformational Change in CD3
(A) T1 hybridoma T cells were incubated with 500 nM of KdpepABA monomer, 5 nM of KdpepABA tetramer, or 5 mg/ml of CD3 antibody (145-2C11)
corresponding to maximal TCR-CD3 binding. Cells were UV irradiated to covalently crosslink the MHCp to the TCR-CD3. Upon lysis, the Nck pull-
down assay was performed and TCR-CD3 detected by anti-z and anti-CD33 immunoblotting (top). As control, an aliquot of each lysate was subjected
to anti-z immunoblotting to confirm equal amount of TCR-CD3 (middle). Alternatively, an anti-CD3 immunoprecipitation was done and presence of
MHC detected with a b2-microglobulin antibody (bottom).
(B) T1 hybridoma cells were incubated with 50 nM KdpepABA dimer or 5 nM tetramer that resulted in maximal TCR-CD3 binding and subjected to UV
irradiation. Nck pull-down was performed as in (A).
(C) T1 hybridoma was incubated with 5 nM KdpepABA tetramer or 5 mg/ml anti-CD3. Cells were UV irradiated or left untreated and processed as in (A).
(D) Aliquots of the samples from (C) were used to confirm stimuli binding. The tetramer already included streptavidin-PE (middle), and bound anti-CD3
was detected with anti-IgG-PE (bottom). Untreated cells are shown in gray.
(E) T1 hybridoma T cells lacking CD8 expression were stimulated with pepABA-pulsed A20 cells 10 min at 37C. Upon UV irradiation and parafor-
maldehyde fixation, cells were lysed and processed as above. As a control, T1 cells were stimulated with the indicated antibodies or left untreated.
(F) T1 hybridoma T cells expressing CD8 were stimulated with pepABA-pulsed A20 cells, and induction of the conformational change was probed
as in (E).
The results are representative of at least three independent experiments.outside the hapten-binding pockets (Wedemayer et al.,
1997) and because the sc molecule was fused to the
TCR-CD3 via a flexible linker, it is highly unlikely that NIP
binding could transmit a structural change to TCRab.
To test whether monovalent or multivalent engagement
of the scTCRb could induce the conformational change,
we generated a series of peptides in which the number
of NIP molecules coupled to each peptide was increasedfrom one to four (Figure 2B). For comparison, NIP-coupled
bovine serum albumin (BSA) was used in which one BSA
molecule was conjugated on average to 15 NIP molecules
(NIP15-BSA). Stimulations were performed maintaining
equimolar amounts of the NIP moiety (Figure S3). The
monovalent NIP1 peptide did not induce the conforma-
tional change (Figure 2C, lane 2), nor did monomeric
free hapten (data not shown). However, as the numberImmunity 26, 43–54, January 2007 ª2007 Elsevier Inc. 45
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TCR-CD3 Conformational Change in T Cell ActivationFigure 2. Simultaneous Engagement of Several TCRab Is Sufficient to Induce the Conformational Change
(A) scTCRb is composed of the NIP binding variable immunoglobulin domains of a NIP antibody connected by a flexible linker of 8 amino acids to the N
terminus of wild-type TCRb.
(B) The sequence of the peptides that contain the NIP-conjugated lysine are shown. The one letter code for amino acids is used. The first number in the
name of the peptide indicates the number of NIP-conjugated lysines and the second number indicates the number of amino acids between two ad-
jacent NIP-conjugated lysines.
(C) 31-13.scTCRb cells were stimulated with the indicated NIP-coupled peptides (lanes 2–5), NIP15-BSA, anti-CD33 (UCHT1), or left untreated. Con-
centrations of the NIP-coupled reagents were chosen in order that the number of NIP molecules per stimulation was constant. After lysis, the Nck pull-
down assay was performed as in Figure 1.
(D) 31-13.scTCRb cells were either stimulated with equal molarities of the indicated peptides or left untreated. Upon lysis, the Nck pull-down was
assayed as in (C).
(E) 31-13.scTCRb cells were stimulated at 37C or on ice in the presence of azide. Alternatively, a membrane fraction of 31-13.scTCRb cells was in-
cubated with the stimuli on ice, or stimuli were added to the detergent lysates. The stimuli were NIP15-BSA and CD3 antibody. The Nck pull-down
assay was done as in (C).
(F) A membrane fraction of SRD10 cells was incubated on ice with anti-CD3 (145-2C11) or anti-TCRab (3D3). Alternatively, the antibodies were added
to the lysates. After lysis of the membranes, the Nck pull-down assay was done as above. As control for antibody binding, protein G-coupled sephar-
ose was incubated with the corresponding lysates and the presence of the antibody-TCR-CD3 complex was assayed (bottom).
The results are representative of at least three independent experiments.46 Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc.
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CD33 became increasingly accessible (Figure 2C). Thus,
simultaneous engagement of several TCR-CD3 com-
plexes, but not a change in the TCRab structure, is neces-
sary and sufficient to induce the conformational change.
We then examined how the distance between two NIP
ligands influences the ability to induce the conformational
change. To this end, we synthesized peptides with varying
numbers of amino acids between two NIP-conjugated ly-
sines. The NIP2.0 peptide contained no spacer between
the two NIP lysines, the NIP2.3 peptide has a three amino
acid spacer, etc. (Figure S3). An increase in the distance
between the two haptens within a peptide resulted in de-
creased induction of the conformational change (Fig-
ure 2D). With a spacer of 24 amino acids or more, the pep-
tide ligands did not induce the conformational change. We
excluded the possibility that the bivalent NIP peptides
bound to two TCR-CD3s on two different T cells (Fig-
ure S4). Hence, our data indicate that two TCRab have
to be brought into close proximity and/or in a specific ori-
entation in order to transduce the conformational change.
The Mobility Restriction Imposed by an Intact
Membrane Is Necessary to Induce the
Conformational Change via TCRab
The above results argue that two or more TCR-CD3s have
to be contacted in order to change their conformation.
This does not depend on metabolic processes because
the PRS was also exposed when T cells were stimulated
in the presence of azide at 0C (Figure 2E, lanes 4–6).
The conformational change also occurred on isolated
membrane patches prepared in the absence of detergent,
indicating that cytosolic proteins were not involved in the
process (lanes 7–9). However, when detergent-solubilized
TCR-CD3s were incubated with NIP15-BSA, the confor-
mational change was not induced (lane 12). We could
not demonstrate that NIP15-BSA bound to TCR-CD3 in
the lysate. Therefore, we repeated the experiment with
SRD10 cells stimulated with an idiotypic antibody. The
TCRab antibody induced the conformational change on
membrane preparations but not in detergent lysates
(Figure 2F, lanes 3 and 6). Here we demonstrated that
the antibody was bound to the TCR-CD3 in the lysates
by immunoprecipitation with ProteinG-Sepharose beads
(Figure 2F, bottom). In both experiments, anti-CD33 in-
duced the conformational change in detergent lysates
by binding directly to CD33 (Figures 2E and 2F). These re-
sults indicate that induction of the conformational change
via TCRab clustering requires an intact membrane.
The Conformational Change in CD3 Reverts upon
TCRab-Ligand Dissociation
As we showed in Figure 1, covalent fixation of the T1 TCR-
CD3 to its cognate MHCp was necessary to detect the
conformational change in CD33. This could be explained
if the conformational change was reverted upon ligand de-
tachment during cell lysis. To directly test this hypothesis,
we used our scTCR system, in which the ligand can be re-
moved under controlled conditions (Figure 3A). Binding ofthe sc antibody Ac146 to the hapten-recognition site of the
sc domain was inhibited by incubation with the free hapten
NIP (Reth et al., 1979). When 31-13.scTCRb cells were in-
cubated with the sc antibody, the conformational change
was detected (Figure 3B, lanes 5 and 7). However, the
conformational change was reverted when the sc anti-
body was removed by adding an excess of monovalent
NIP to the living cells (lanes 6 and 8). Note that similar to
Figure 3. The Conformational Change Is Reversible
(A) 31-13.scTCRb cells were left unstimulated and either subsequently
treated with 1 mM free monomeric NIP (top, solid line) or left untreated
(gray graph). Alternatively, the cells were stimulated with anti-CD33 and
either treated with free NIP (second panel, solid line) or left untreated
(gray graph). Lastly, sc antibody (10 mg/ml, third panel or 30 mg/ml,
last panel) was used, in combination with or without subsequent elution
with NIP (solid line or gray graph, respectively). Cells were stained with
anti-IgG and analyzed by flow cytometry.
(B) Anti-CD33 (10 mg/ml) and anti-sc (10 mg/ml or 30 mg/ml)-stimulated
31-13.scTCRb cells were left untreated (lanes 3, 5, 7) or treated with
1 mM NIP (lanes 4, 6, 8). The Nck pull-down assay was performed as
in Figure 1. Protein G-coupled sepharose was incubated with an aliquot
of the corresponding lysates and the presence of antibody-TCR-CD3
complexes was assayed (bottom). The samples were from the same
experiment as in (A).
The results are representative of at least four independent experiments.Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc. 47
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Required for TCR-CD3 Signaling
(A) 31-13.scTCRb cells were incubated with
the indicated stimuli 3 min at 37C. The stimuli
were: 5 mg/ml of the anti-CD3-Fab fragment or
the CD3 antibody (OKT3) as well as 2.8 3 104
NIP molecules/ml of the NIP2.200 peptide.
Upon lysis, the Nck pull-down assay was per-
formed as before.
(B) Stimulation of 31-13.scTCRb cells was
done as in (A). After lysis, an anti-phosphotyro-
sine immunoprecipitation was carried out and
the purified proteins were detected by anti-z
immunoblot (top). Anti-z immunoblotting of an
aliquot of the lysate verifies equal loading.
(C) 31-13.scTCRb cells were stimulated as in
(A). The lysate was separated by SDS-PAGE
and the indicated proteins were detected by
immunoblotting with anti-phospho-tyrosine
(4G10) or anti-phospho-specific antibodies as
indicated. Anti-actin immunoblotting serves
as control.
The results are representative of at least three
independent experiments.the bivalent NIP2 peptides (Figure 2C), the anti-sc anti-
body is a weak inducer of the conformational change.
As a control, incubation of 31-13.scTCRb cells with mono-
meric NIP had no effect on the conformational change
induced by anti-CD3 (Figure 3B, lanes 3 and 4). Taken
together, these results as well as those observed for
the MHCp and the T1 TCR-CD3 (Figure 1) show that the
TCR-CD3 reverts to its basal conformation when the
stimulus dissociates.
The Conformational Change Is Necessary
for T Cell Activation
Whereas overexpression of the CD33 binding SH3 domain
of Nck (SH3.1) inhibited T cell activation (Gil et al., 2002),
mutation of the PRS in CD33 did not affect T cell develop-
ment or antibody stimulation of T cells (Szymczak et al.,
2005). Therefore, it is controversial whether Nck recruit-
ment is important for T cell activation. We should stress
that the Nck pull-down, and therefore the exposure of
the PRS, is used in this study as a marker for the presence
of the conformational change. However, because in addi-
tion to Nck the conformational change possibly has other
effectors, we addressed whether lack of conformational
change impairs T cell activation. 31-13.scTCRb cells
were stimulated with NIP-coupled peptides containing
two NIP moieties separated by spacers of different length.
Induction of the conformational change (Figure 2D) corre-
lated with the ability of the NIP-modified peptides to stim-
ulate Ca2+ influx and to upregulate the activation marker
CD69 (Figure S5). Hence, poor inducers of the conforma-
tional change were also inefficient T cell activators.48 Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc.To directly assess whether the conformational change is
required for T cell activation, we used two different re-
agents. First was the NIP2.200 peptide, which does not in-
duce the conformational change (Figure 2D) but simulta-
neously binds to two TCR-CD3s, and second was a Fab
fragment of the CD3 antibody OKT3, which induces the
conformational change (Figure 4A; Gil et al., 2002) but
does not cluster the TCR-CD3. Simultaneous incubation
with both reagents induced the conformational change
(Figure 4A). When z phosphorylation was measured, we
found that either stimulus alone was hardly active
(Figure 4B), whereas both together induced strong phos-
phorylation, similar to that evoked by stimulation with biva-
lent anti-CD3 (Figure 4B). Thus, induction of the conforma-
tional change is required, but not sufficient, for optimal z
phosphorylation.
Phosphorylation of TCR-CD3 leads to the recruitment of
ZAP-70, which in turn phosphorylates several substrates
including the adaptor proteins LAT and SLP-76. These
proteins serve as docking sites to organize multiprotein
complexes resulting in phosphorylation of phospholipase
Cg1, the MAP kinases ERK1 and ERK2, and activation of
gene transcription factors such as NF-AT and NF-kB. To
study the contribution of the conformational change to
these events, we analyzed phosphorylation of several
substrates with phospho-specific antibodies (Figure 4C).
Only the simultaneous stimulation with anti-CD3-Fab frag-
ments and NIP2.200 peptide caused substantial phos-
phorylation of LAT, PLCg1, and ERK.
An important early event upon TCR-CD3 triggering
is Ca2+ flux into the cytoplasm. Stimulation with
Immunity
TCR-CD3 Conformational Change in T Cell ActivationFigure 5. The Exposure of the PRS Is Crucial for T Cell Activation
(A) 31-13.scTCRb cells were loaded with Indo-1 and stimulated with the indicated reagents (concentrations as in Figure 4) to induce Ca2+ responses.
Equal molarities of the NIP-coupled peptides were used. The Indo-1 ratio was integrated over 10 min and measured by flow cytometry. The stimuli
were added after 1 min (arrow).
(B) Upon transfection with an NF-AT (left) or an NF-kB (right) reporter plasmid, 31-13.scTCRb cells were incubated 6 hr with the described stimuli and
lysed, and luciferase activity was assayed relative to unstimulated cells. The mean of three independent, simultaneously performed stimulations is
shown. Error bars indicate standard deviation.
The results are representative of at least five independent experiments.anti-CD3-Fab or NIP2.200 peptide alone was not suffi-
cient to induce a Ca2+ response. However, combination
of both stimuli induced a strong Ca2+ flux indistinguishable
from the one elicited by the other NIP2 peptides (Figure 5A).
This indicates that it was the inability of the NIP2.200 pep-
tide to induce the conformational change that accounted
for its poor activity. These data also show that the distance
of the two NIP moieties on the peptides did not play a sub-
stantial role in activation, as long as the conformational
change is induced. The need for TCR-CD3 clustering
wasalsodemonstrated in thissystem,becauseacombina-
tion of the monovalent NIP1 peptide with the Fab fragment
did not give any Ca2+ response, whereas clustering the Fab
fragment with light chain antibodies did result in Ca2+ flux
(Figure S5). In agreement with these results, optimal acti-
vation of NF-AT and NF-kB (Figure 5B) was detected
only in the presence of both TCR-CD3 clustering and con-
formational change in the 31-13.scTCRb cell line. Stimula-
tion with the Fab fragment alone resulted in some activity,
probably resulting from Fab multimerization by the tissue
culture plate.To confirm our data with primary T cells, we transiently
transfected human peripheral blood mononuclear cells
(PBMCs) with an expression vector encoding for the
scTCRb chain together with a GFP marker for transfected
cells. Only stimulation with the anti-CD3-Fab and the
NIP2.200 peptide resulted in a marked CD69 upregulation
in the transfected, GFP-positive cells. As a control, no ef-
fect of the NIP2.200 peptide was seen in nontransfected,
GFP-negative cells (Figure 6).
These results argue that it is possible to separate the
conformational change from TCR-CD3 clustering by in-
creasing the distance between binding groups in a bivalent
ligand. With this approach we demonstrate that the con-
formational change in the TCR-CD3 complex is necessary
for full T cell activation.
DISCUSSION
A key finding of the present study is that the relationship
between the two models of TCR-CD3 triggering, namelyImmunity 26, 43–54, January 2007 ª2007 Elsevier Inc. 49
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ticipated because clustering is required to induce the con-
formational change (summarized in Figure 7). Remarkably,
we found that monovalent engagement of TCRab by
MHCp or anti-TCRab Fab fragments did not transmit
a conformational change to the cytoplasmic region of
CD33, whereas bivalent and multivalent engagement
did. This implies that TCRab ligation per se is not sufficient
to transmit structural alterations through the TCRab heter-
odimer to the CD3 subunits. Indeed, ligand binding gener-
ates induced-fit type changes only in the variable TCRab
regions at the ligand-binding interface (Bankovich and
Garcia, 2003; Reiser et al., 2002; Rudolph et al., 2006;
Wu et al., 2002), but no alterations at the distal portions
of the heterodimer, which are connected to the CD3 units.
Note that unlike Fab fragments of antibodies against
TCRab, Fab fragments of the CD3 antibodies OKT3 and
UCHT1 induce the conformational change by binding di-
rectly to CD33 (Figure S6).
To combine the rigidity of TCRab with the presence of
conformational changes in CD3, a piston-like model, in
which TCRab are displaced perpendicular to the mem-
brane, and a rotational model, where TCRab rotate with
respect to CD3, have been proposed (Choudhuri et al.,
2005; Gil et al., 2005; Sun et al., 2001). These models imply
that the ligand exerts a mechanical force on TCRab, which
is possible only if a second fixed interaction is present. The
coreceptors CD8 and CD4 could theoretically provide this
interaction. We show that soluble bivalent MHCp or pep-
tide-pulsed APCs induce the conformational change in
the CD8-negative T1 hybridoma, indicating that CD8 is
not involved in inducing the conformational change. Fur-
thermore, anti-TCRab can induce the conformational
change in the absence of any additional interaction. How-
Figure 6. The Conformational Change Is Required for T Cell
Activation in Human PBMCs
Human PBMCs were transiently cotransfected with vectors encoding
for scTCRb and GFP. The cells were stimulated (concentrations as in
Figure 4) 24 hr or left untreated. After staining with a CD69 antibody,
cells were analyzed by flow cytometry gating on GFP-positive (left)
and GFP-negative (right) cells. The relative increase was calculated
considering the percent of CD69-positive cells upon anti-CD3 stimula-
tion as 100%. The mean of triplicates and the standard deviation are
indicated. The results are representative of at least two independent
experiments.50 Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc.ever, CD8 and CD4 can strengthen the MHCp-TCR-CD3
interaction, and therefore could aid in stabilizing the con-
formational change. Our data thus argue that the second
fixed interaction is the second TCRab. Bivalent ligand
binding could change the relative orientation of two
TCRab dimers toward each other, enforcing cooperative
interactions. After bi- or multivalent binding, the two
TCRab might ‘‘pinch’’ the CD3 subunits so that the extra-
cellular parts of CD3 are pushed away from their original
positions. Because the short stalks connecting the extra-
cellular domains and the transmembrane regions of CD3
appear to be rigid (Arnett et al., 2004; Sun et al., 2001),
such displacement could be transmitted to the transmem-
brane domains, resulting in rearrangements of the cyto-
plasmic tails (Figure 7).
When TCRab were clustered in detergent lysates, the
conformational change in CD33 was not induced. This
indicates that two TCRab need to be brought not only
into close proximity (because increased distance led to
Figure 7. The Permissive Geometry Model of TCR-CD3
Triggering
(A) In absence of ligand binding, the TCR-CD3 complex is in a resting
state.
(B) Clustering of two (or more) TCR-CD3 in a nonpermissive geometry
that does not induce the conformational change is not sufficient for
TCR-CD3 triggering. Inactive clustering is achieved by the NIP2.200
peptide. The TCR-CD3 might also be preclustered in the nonpermis-
sive geometry before ligand binding (Schamel et al., 2005).
(C) Monovalent MHCp binding does not lead to a structural change of
the TCRab heterodimer, thus not rearranging the cytoplasmic tails of
CD3. Consequently, TCR-CD3 is not triggered.
(D) Bivalent (and multivalent) MHCp binding does not change the
structure of one TCRab outside the direct contact region. Since two
TCR-CD3 are engaged simultaneously, they have to adjust to the ge-
ometry of the preformed MHCp dimer. This results in a reorientation of
two TCRab into a permissive geometry, thereby ‘‘pushing and squeez-
ing’’ the extracellular and transmembrane regions of the CD3 and z
subunits (arrows). The rearrangement is transmitted through the mem-
brane and affects the conformation of the cytoplasmic regions of CD3.
(E) Fab fragments of CD33 antibodies alter the conformation of CD3 by
the monovalent direct binding event. The conformational change alone
is not sufficient for TCR-CD3 triggering and T cell activation.
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within the constraints of the membrane. If the TCR-CD3
dimer does not have the right orientation, the conforma-
tional change is not induced. Thus, inducing proximity of
two TCRab is necessary, but not sufficient, to generate
the conformational change. Likewise, not all TCR-CD3 an-
tibodies have the same capability to induce the conforma-
tional change, even when they bind to the same number of
TCR-CD3s. Because these antibodies bind to distinct re-
gions of TCR-CD3, they should lead to different geome-
tries of the clustered complex. We therefore suggest
that the exact geometry determines whether a conforma-
tional change takes place or not. A permissive geometry
would lead to structural reorganization to expose the
PRS of CD33, whereas a different inert geometry would
not (permissive geometry model).
Further support for the permissive geometry model
comes from our experiments with the scTCRb chimera,
in which the hapten binding domain (sc) is connected via
a flexible linker to TCRb. Engagement by a bivalent hapten
or a bivalent anti-sc antibody probably brings two TCRab
together in a random geometry. Therefore, only a few
TCR-CD3 form the correctly oriented clustered ab-ab
complex capable of communicating the conformational
change to CD3. Increasing the valence of the haptenated
peptides augments the probability of creating permissive
geometries, which explains the increase in conformation-
ally changed TCR-CD3s. Even NIP15-BSA was less effi-
cient than anti-CD3 to induce the conformational change.
In contrast, MHCp dimers, tetramers, and anti-CD3 were
equally potent in inducing the conformational change,
suggesting that because of conserved interactions be-
tween two MHCp molecules (Krishna et al., 1992; Schafer
et al., 1995), the binding of dimeric MHCp already places
all TCR-CD3s in the permissive geometry. Thus, TCR-CD3
dimers in the permissive geometry are necessary and
sufficient to induce the conformational change of the
TCR-CD3 complex.
In the present study, we address for the first time the im-
portance of the ligand-induced conformational change in
CD3, in contrast to previous reports that have studied
only the role of the PRS of CD33 (Szymczak et al., 2005)
or the recruitment of Nck to this PRS (Gil et al., 2002).
One of the consequences of the conformational change
is the exposure of the PRS of CD33 (Gil et al., 2002). By
the use of a mutant TCR-CD3 complex lacking the PRS
of CD33 (Szymczak et al., 2005), only the importance of
the PRS can be studied and not the role of the conforma-
tional change itself. To directly study the contribution of
TCR-CD3 clustering and conformational changes to TCR
activation, we used the Fab fragment of the CD3 antibody
OKT3, which by direct binding induces the conformational
change (Gil et al., 2002) but does not cluster TCR-CD3.
In addition, the NIP2.200 peptide does not induce the
conformational change, but does bind simultaneously to
two TCR-CD3s. By combining the NIP2.200 peptide and
anti-CD3 Fab, we show that both TCR-CD3 clustering
and conformational changes are needed for optimal
T cell activation.The necessity of the conformational change for effective
TCR-CD3 signaling in combination with the permissive ge-
ometry model might also explain the fact that all TCRab
adopt a diagonal orientation on MHCp (Rudolph et al.,
2006). Conserved MHCp-TCR-CD3 interactions that
dictate this orientation are not apparent. We suggest
that initially other orientations exist, but that the MHC
self-peptide-TCR-CD3 interaction in the thymus selects
those TCR-CD3s that bind to multivalent MHCp in the per-
missive geometry, i.e., the conformational change might
be necessary for thymic selection to guarantee optimal
T cell activation in the periphery. In addition, the diagonal
orientation might ensure that MHCp-bound CD8 or CD4
will contact the TCR-CD3 complex at the correct position
(Bankovich and Garcia, 2003; Buslepp et al., 2003; Gar-
boczi et al., 1996).
Recently, a pseudodimer model of TCR activation was
proposed, providing a theoretical background of how sol-
uble MHC agonist-MHC self-peptide heterodimers can
activate T cells (Krogsgaard et al., 2005). Our permissive
geometry model provides an alternative explanation. Pre-
formed TCR-CD3 oligomers (Schamel et al., 2005), which
bind dimeric MHCp with higher avidity than TCR-CD3
monomers, are in a nonpermissive geometry (Figure 7B).
Binding of the MHCp heterodimers to the oligomeric
TCR-CD3 would induce the permissive geometry and
therefore T cell triggering (Figure 7D). The role of CD4
would be to stabilize the interaction between MHCp and
TCR-CD3 and to recruit additional kinases.
Lastly, we show that removal of MHCp tetramers or
stimulating antibody reverts the conformational change
in the TCR-CD3. Thus, the conformational change is not
the molecular event that marks activated TCR-CD3s after
MHCp dissociation, which could lead to TCR-CD3 inter-
nalization (Coombs et al., 2002), or accumulation during
serial triggering (Valitutti et al., 1995). It might be, however,
one of the events that directly communicate MHCp bind-
ing to the cytoplasmic signaling machinery. Conse-
quently, the duration of TCR-CD3 ligand engagement
can be measured intracellularly as proposed by the kinetic
proofreading model (McKeithan, 1995). In fact, the combi-
nation of an avidity proofreading model with the require-
ment of conformational changes for T cell activation al-
lowed us to propose recently a thermodynamic model
that accounts for the paradox of the high sensitivity and
low affinity of the MHCp-TCR-CD3 interaction (Schamel
et al., 2006).
In summary, we propose a permissive geometry model
that might explain how ligand binding to the rigid TCRab
subunits is communicated into a conformational change
at the cytoplasmic tail of CD33, which is necessary,
but not sufficient, for full TCR-CD3 triggering and T cell
activation.
EXPERIMENTAL PROCEDURES
Cells
We generated the expression vector pSRscTCRb that encodes
a leader peptide, a signal peptidase cleavage site, the NIP-specificImmunity 26, 43–54, January 2007 ª2007 Elsevier Inc. 51
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and the mature human Vb3 HA1.7 chain. The sc was taken from the
plasmid pL(-I)VHVL-XhRSl-B (Schamel et al., 2003) and the TCRb
sequence from pJ6b (Hewitt et al., 1992). pSRscTCRb was transfec-
ted into the human Jurkat-derived TCRb-negative line 31-13 to yield
31-13.scTCRb (Figure 2A).
The murine T cell line SRD10 and the T1 hybridoma (T1.4 CD8 and
T1 CD8+) have been described (Luescher et al., 1995; Rojo and Jane-
way, 1988). Murine A20 cells were used as antigen-presenting cells. All
cells were maintained in complete RPMI-1640 with 5% serum. T cell
clones from T1 transgenic mice were culture as described (Doucey
et al., 2003). Human peripheral blood mononuclear cells were isolated
from healthy donors according to the local ethics committees on
human experimentations via a Ficoll gradient and cotransfected with
the pSRscTCRb and pCMV-GFP plasmids with the Human T Cell
Nucleofector Kit (Amaxa GmbH).
Antibodies and Reagents
The rabbit anti-z antiserum 448 has been described (San Jose et al.,
1998). The following antibodies were used: UCHT1 (anti-human CD3,
P. Beverly, UK), 145-2C11 (anti-mouse CD3, J. Bluestone, USA),
anti-sc (Ac146, M. Reth, Germany), 3D3 (anti-mouse Va/b, J.M.
Rojo, Spain), and anti-b2microglobulin (T. Dick, Germany). Other anti-
bodies were purchased as follows: OKT3 (anti-human CD3) from Or-
tho, anti-mouse IgG-PE or IgG-FITC, anti-mouse kappa from Southern
Biotech, anti-phospho-LAT (Y191) from Cell Signaling, anti-activated
MAPK (12D4) from Nanotools, and anti-phopho-PLCg (Y383), anti-
actin (I-19), and anti-CD33 (M20) from Southern Biotech. OKT3-Fab
fragments were prepared with the Immunopure IgG1-Fab Preparation
kit and confirmed by SDS-PAGE and immunoblotting. Secondary
antibodies for western blot were obtained from Southern Biotech. NIP
(nitro-iodo-phenol)-conjugated BSA (15 haptens per BSA molecule)
and free NIP were purchased from Biosearch Technologies (Novato,
CA). All NIP peptides were synthesized by IRIS Biotech. Streptavi-
din-PE was purchased from Molecular Probes. PbCS(ABA) peptide
(pepABA) was synthesized as described (Luescher et al., 1991). Solu-
ble monomeric, dimeric, and tetrameric KdpepABA complexes were
prepared as described (Cebecauer et al., 2005; Gregoire et al., 1996;
Kalergis et al., 2000).
Cell Stimulations and Lysis
Cells were harvested, resuspended in medium without serum, and in-
cubated 1 hr at 37C prior to stimulation with the indicated stimulus at
37C. Alternatively, cells were resuspended in PBS with 2% serum and
0.01% NaN3 and stimulated at 0
C. The different NIP-coupled re-
agents were used at the same concentration of the NIP hapten per
stimulation. The optimal concentration to stimulate 31-13.scTCRb
cells was determined empirically based on the induced tyrosine-phos-
phorylation in cellular lysates (data not shown). This concentration (2.8
3 104 NIP molecules/ml) was used in all experiments. T1.4 cells were
incubated with the KdpepABA complexes in medium without serum for
1 hr at 0C. After UV irradiation, cells were harvested and lysed. A20
cells were loaded overnight with 1 mM of PbCS(ABA) peptide by incu-
bation in complete medium with 1% serum. After PBS washing, A20
and T1 hybridoma cells were brought into close contact by centrifuga-
tion and incubated 10 min at 37C. A ratio of four APCs per T cell was
used. Upon UV irradiation and 1% formaldehyde fixation in PBS, cells
were lysed. Membrane fractions were prepared by disrupting 3 3 107
cells in hypotonic buffer (10 mM HEPES [pH 7.4], 42 mM KCl, 5 mM
MgCl2, and protease inhibitors) with a Dounce homogenizer and pellet-
ing the membranes in an ultracentrifuge at 150,000 3 g. NIP elution
was performed by incubation with 1 mM of free NIP 1 hr at 4C. All ly-
ses were done in 1 ml lysis buffer containing 20 mM TrisHCl (pH 8), 137
mM NaCl, 2 mM EDTA, 10% glycerol, 10 mg/ml leupeptin, 10 mg/ml
aprotinin, 1 mM PMSF, 500 mM sodium orthovanadate, 1 mM NaF,
and 0.5% Brij96.52 Immunity 26, 43–54, January 2007 ª2007 Elsevier Inc.SH3.1(Nck) Pull-Down Assay, Immunoprecipitation,
and Immunoblotting
Postnuclear fractions were subjected to the SH3.1(Nck) pull-down as-
say as described (Gil et al., 2002). TCR-CD3 immunoprecipitations
were performed with 5 mg of anti-CD3 antibodies overnight at 4C.
Phosphotyrosine immunoprecipitations were performed with PT-66
agarose from Sigma. Samples were subjected to SDS-PAGE separa-
tion and transferred to PVDF membranes. Immunoblotting was per-
formed by conventional methods.
T Cell Activation Assays
Ca2+ Influx
Cells resuspended in medium with 1% serum were incubated with
5 mg/ml of Indo-1 and 0.5 mg/ml of pluronic F-127 (both Molecular
Probes) 45 min at 37C. After washing, cells were resuspended in me-
dium with 1% serum and kept on ice. Ca2+ response was induced by
addition of the indicated stimulus 1 min after starting to record the ratio
of Ca2+-bound Indo-1 versus unbound Indo-1 with a LSRII fluores-
cence spectrometer (Becton Dickinson). Data were analyzed with
the FloJo 6.1 software.
Luciferase Assay
For the measurement of transcriptional activity, 3 3 107 cells were
transiently transfected with 30 mg of NF-AT-luciferase (Hoey et al.,
1995) or NF-kB-luciferase (Minguet et al., 2005) reporter plasmids by
electroporation. Cells were grown for 24 hr, harvested, resuspended
in medium with 0.5% serum, and stimulated 6 hr as indicated. After
harvesting, the cells were lysed and luciferase activity measured with
the Luciferase assay system from Promega.
Upregulation of CD69
Cells were stimulated for 24 hr with the indicated stimuli. After harvest-
ing, cells were stained with an CD69-PE antibody (Caltag Laboratories)
and analyzed by flow cytometry.
Supplemental Data
Six Supplemental Figures can be found with this article online at http://
www.immunity.com/cgi/content/full/26/1/43/DC1/.
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